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Introduction
Currently, there are approximately 3.2 million children living with
HIV worldwide [1]. Although the number of new infections in
children has decreased in the last few years, 240,000 new
paediatric HIV infections still occurred in 2013, mainly in
resource-limited countries [1]. Mother-to-child transmission
(MTCT) is the main source of paediatric HIV infection. Most cases
of MTCT occur around the time of delivery, but may also occur
in utero or postnatally through breastfeeding; without prevention,
the overall risk of transmission via breastfeeding is up to 40% [2].
Disease progression in HIV-infected infants is more rapid than in
HIV-infected adults and, in the absence of antiretroviral
treatment, about one-third of perinatally HIV-infected infants
progress to early AIDS within 2 years of life [3,4].
The introduction of combined antiretroviral therapy (cART) has
dramatically reduced MTCT of HIV to less than 2% in
high-income countries and has also given rise to substantial
improvements in terms of survival and quality of life in
HIV-infected children [5]. Despite these advances, about
200,000 children still died from HIV-related causes worldwide in
2013 [1] and many efforts are still required to implement
prevention of MTCT (PMTCT) and reduce disease progression
in HIV-infected children.
In recent years, several virological and immunological ﬁndings
have suggested that a threshold level of the virus is required to
establish systemic and persistent HIV infection in the host. This
level depends on virus–host interactions. The paediatric model
affords several advantages for studying virus–host interactions,
including knowledge of viral source and time of exposure. While
the use of cART at birth may impede or reduce the level of the
transmitted/infecting virus, the host’s genetic variants of viral co-
receptors and innate immunity, the earliest response to microbial
entry and injury, may affect perinatal HIV infection and early
disease progression. The effects of innate immunity/genetic
resistance to HIV may be of particular importance in infants
because they are exposed to HIV and acquire infection when their
adaptive immune system is still developing.
Mother-to-child transmission of HIV and
establishment of perinatal HIV infection:
critical questions
A large number of factors are involved in MTCT of HIV [6–11].
The type and length of exposure and maternal level of plasma
viraemia are key determinants for MTCT. In the European
Collaborative Study, the risk of transmission increased from 2- to
3.5-fold for each log increase of maternal plasma viraemia and,
adjusted for maternal viral load, vaginally delivered immature
neonates (born before 37 weeks of gestation) have a 10-fold
higher risk of acquiring infection than infants born at term by
Caesarean section [6]. HIV infection acquired during pregnancy
or postpartum and co-infections, which target the placenta, fetal
membranes, genital tract and breast tissue, also increase the risk
of transmission [10,11].
It is noteworthy that a large percentage of infants born to
HIV-infected mothers escape HIV infection, even in the absence
of ART-based prophylaxis, thus providing evidence of an innate
resistance/immunity to HIV. The failure to establish a persistent
chronic infection may be due to ‘irreconcilable incompatibilities’
between virus and host. A few studies in newborns have indicated
that, although MTCT of HIV does occur, the virus cannot
establish a persistent infection in the host, thus raising the
possibility of transient infection followed by natural clearance of
HIV. In most of these cases, when the virus was detected early in
life, either by virus isolation or proviral sequence detection by the
polymerase chain reaction, HIV could no longer be detected in
peripheral blood cells a few weeks later. All children remained
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Abstract
A body of evidence indicates that a threshold level of the virus is required to establish systemic and persistent HIV infection
in the host and that this level depends on virus–host interactions. Mother-to-child transmission (MTCT) of HIV is the main
source of paediatric HIV infection and occurs when the host’s immune system is still developing. Thus, innate resistance
and immunity, rather than adaptive immune response, may be the main drivers in restricting the establishment of HIV
reservoirs and the long-lived persistence of HIV infection in infants. Genetic variations in HIV co-receptors and their
ligands, as well as in Toll-like receptors and defensins, key elements of innate immunity, have been demonstrated to
inﬂuence the risk of perinatal HIV infection and disease progression in HIV-infected infants. Early treatments with combined
antiretroviral therapy (cART) restrict paediatric infection by reducing the level of the transmitted/infecting virus to below
the threshold required for the onset of immune response to the virus and also signiﬁcantly reduce HIV reservoirs. However,
despite long periods with no signs and symptoms of HIV infection, all early cART-treated children who later discontinued
cART had a rebound of HIV, except for one case in whom a period of viral remission occurred. Which parameters predict
viral remission or viral rebound after cART discontinuation? Could early cART prevent rather than just reduce the
establishment of viral reservoirs? And, if so, how? Answers to these questions are also important in order to optimise the
use of early cART in infants at high risk of HIV infection.
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seronegative and without signs of infection [12–16]. It should be
stressed that the clearance of the virus was based on the lack of
HIV detection in peripheral blood cells combined with the lack of
immunity against HIV. However, it was not clear whether these
cases represented true transient infections or whether the virus
was persistently below a threshold level in some cellular
sanctuaries. Notably, one infant, who apparently cleared the virus
within the ﬁrst few months of life, showed a marked fall in CD4+
T cell count over 9 years of follow-up, in the absence of other
laboratory and clinical signs of HIV infection [17]. Unfortunately,
no further data are available on this patient. Persistence of HIV
DNA integrated in the genome of peripheral blood cells has been
described in a few children at 2 years of age belonging to a
paediatric cohort of HIV-seronegative children born to HIV-
seropositive mothers [16]. However, the possibility of a transient
infection is debatable, as the particular HIV life-cycle (i.e. reverse
transcription of viral RNA genome into proviral DNA once the
virus has entered the host cell, and integration of proviral DNA
into the host genome) and the natural clearance of HIV is still an
open question.
ART-based prophylaxis, including treatment of mothers during
pregnancy, delivery, and post-delivery in neonates, is well known
to reduce the rate of MTCT by 98%. When short regimens of
prophylaxis were initiated in neonates within 3 days of birth, the
rate of infection fell by 20–30% [18]. A single dose of nevirapine
administered within 24 hours after birth to infants born to
cART-untreated HIV-infected mothers has been shown to reduce
rate of MTCT by 40% [19]. This reinforces the concept of efﬁcacy
of post-exposure prophylaxis and the possibility that, in certain
settings, the transmitted virus is unable to establish a systemic
chronic infection.
Once HIV infection in infants is established, it is characterised by
a rapid increase in HIV RNA in plasma and HIV DNA in peripheral
blood cells within the ﬁrst 2–3 months of life. Unlike in adults,
where the primary infection is followed by a viral decline
associated with serological and cellular immune response to HIV,
in children plasma viraemia declines more slowly and remains at
high steady-state levels in infants who rapidly progress to early
AIDS by 2 years of age [20]. The immune system of
neonates/infants is still developing, and thus the adaptive
immune response against HIV is delayed compared to adults. This
concept is supported by the low adaptive immune response
observed in HIV-infected infants during the ﬁrst year of life [21],
and by the lack of autochthonous antibody production in
HIV-infected infants who initiated cART within 3 months of
life [22,23]. Thus, other factors may contribute to controlling viral
replication soon after primary infection in non-rapid
progressor infants.
The key aspect of life-long persistence of HIV infection is the
presence of HIV reservoirs. HIV preferentially infects memory
CD4+ T cells. Limited HIV infection of central memory and stem
cell memory CD4+ cells is associated with lack of progression in
viraemic individuals [24]. Factors that prevent/limit the
establishment of HIV reservoirs are critical to prevent/restrict
paediatric HIV infection and disease progression (Figure 1).
Role of HIV co-receptors and their ligands
HIV is characterised by a high degree of genetic and phenotypic
variability, including its exploitation of receptors to enter target
cells. Among the panoply of molecules known to work in
conjunction with the CD4 molecule, the main receptor for HIV,
two chemokine receptors, CCR5 and CXCR4, have been identiﬁed
as the major HIV co-receptors. According to co-receptor use, the
viruses isolated from patients, i.e. the primary isolates, have been
classiﬁed as R5 and X4, respectively. The origin of infection is
monophyletic: only one or a few variants are transmitted from
mother to child, and these variants are mainly of R5 type, even
when the mother harbours a mixture of R5 and X4 viral
variants [25]. Although the few infants born with X4 type isolate
rapidly develop AIDS, most cases of early AIDS are due to the R5
type variants [26–28]. Genetic polymorphisms of HIV
co-receptors and their ligands may restrict virus infection
(Table 1). A 32-nucleotide deletion (Δ32) in the CCR5
gene-coding region prevents protein expression on the cell
membrane and confers resistance to infection by R5-type
isolates [29]. Haplotye P1/P1 and speciﬁc single nucleotide
polymorphisms (SNP), which increase or decrease CCR5
expression, inﬂuence the risk of perinatal HIV infection and/or
the onset of early AIDS [26,28,30–33]. A SNP in the CCR5
regulatory region is in linkage disequilibrium with an SNP in the
coding region of the CCR2 gene: rs1799864A/A (CCR264I) is
associated with a low risk of early AIDS [30,32].
Chemokines, natural ligands of viral co-receptors, can inhibit HIV
infection [34]. The β-chemokines CCL3, CCL4 and CCL5 are
natural ligands of CCR5; their over-expression in exposed
uninfected infants suggests their possible role in mediating
inhibition of perinatal infection [35]. While multi-copies of the
CCL3L1 gene confer a slight increase in the CCL3 level [36], a
reduced ability to produce this chemokine is associated with
increased susceptibility to perinatal infection [37,38].
HIV variability increases over time in both rapid and non-rapid
progressors; viruses using CXCR4 co-receptor emerge during the
course of infection and are detected in nearly half the cases of
late AIDS. Stromal cell-derived factor-1 (SDF1) is an
α-chemokine, a natural ligand of the CXCR4 receptor, and it may
interfere with HIV infection by X4 type isolates. The SDF1 gene
exhibits genetic polymorphisms, including the SNP 3’G/A,
located in the 3’ untranslated region of the gene, which may
serve as a target for cis-acting factors, thus inﬂuencing the
expression of the chemokine. This SNP does not inﬂuence the
risk of MTCT and early AIDS, mainly due to R5 type isolates, but
it accelerates disease progression and increases the risk of late
AIDS [28,30,39].
Dendritic cell-speciﬁc ICAM-3 grabbing-nonintegrin (DC-SIGN) is
an HIV receptor that enhances virus transmission to T cells and is
expressed on placental macrophages. Speciﬁc haplotypes of DC-
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Figure 1. Model of host factors and early treatment to prevent/restrict HIV infection
in infants. Post-exposure cART-based prophylaxis and host factors,
e.g. speciﬁc variants of HIV co-receptors and key components of innate
immunity, may prevent establishment of HIV infection (- - -). Early cART in
HIV-infected children reduces HIV reservoirs and HIV replication to under
the level required for onset of speciﬁc HIV-immune responses. According to
the size of the viral reservoir, which may also be dependent on the time of
cART initiation, interruption of cART is followed by variable HIV response,
i.e. from prompt rebound of plasma viraemia (—) to a long period of viral
remission (- - -), after cART suspension.
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SIGN and of DC-SIGN-related gene (DC-SIGNR ) inﬂuence the
risk of intrauterine and intrapartum MTCT of HIV [40,41].
An intriguing role is exerted by the genetic variants of the MDR1
gene, which codes for the drug transporter P-glycoprotein
(P-gp). Besides their impact in modulating P-gp expression and
drug response, in vitro assays have indicated a decreased HIV
infectivity in cells over-expressing P-gp by affecting viral fusion
and possibly viral release. SNPs and speciﬁc haplotypes have
been associated with slow disease progression, but have no effect
on HIV perinatal infection [42].
Role of innate immunity
Innate immunity provides the ﬁrst line of defence against a wide
range of micro-organisms before the development of adaptive
immune responses: its role in disease outcome is particularly
important in children who acquire infections when their adaptive
immune response is still developing. Toll-like receptors (TLRs)
and defensins, initiators and effectors of innate immunity, have
been described to inﬂuence infection and disease progression in
paediatric HIV/AIDS.
TLRs are type 1 transmembrane proteins differentially expressed
in immune cells, and can recognise and bind pathogen-associated
Table 1. Genetic variants associated with risk of perinatal HIV infection and/or early disease progresson
Gene Genotype Study population (children) Main findings Refs
HIV co-receptors and their ligands
CCR5 rs333wt/Δ32 European and African Low risk of early AIDS [26,32]
Hispanic, non-Hispanic Low risk of early AIDS [30]
Haplotype P1/P1 Italian High risk of early AIDS [26,28]
rs1799987A/A Hispanic, non-Hispanic Rapid disease progression [30]
sub-Saharan African High risk of perinatal HIV infection [31]
rs1800023A/A Brazilian Low risk of perinatal HIV infection [33]
rs41469351C/C sub-Saharan African High risk of perinatal HIV infection [31]
CCR2 rs1799864A/A Hispanic, non-Hispanic Low risk of early AIDS [30]
European and African Low risk of early AIDS [32]
CCL3L1 Low gene copy number South African High risk of perinatal HIV infection [37,38]
SDF-1 rs1801157A/A Italian Accelerated disease progression [39]
Hispanic, non-Hispanic Accelerated disease progression [30]
rs1801157G/A Caucasian No impact on early AIDS, high risk of late AIDS [28]
DC-SIGN Haplotype H2 Zimbabwean Low risk of perinatal HIV infection [40]
Haplotype H4; H6 High risk of perinatal HIV infection
DC-SIGNR Haplotypes H1/H1; H1/H3; Zimbabwean High risk of perinatal HIV infection [41]
H3/H3
Key elements of innate immunity
TLR9 rs352139A/A Caucasian Slow disease progression [50]
rs352140A/A African High risk of perinatal HIV infection [51]
rs352140A/G Caucasian Rapid disease progression [50]
Haplotype Caucasian Low risk of perinatal HIV infection [49]
rs352139G/rs352140A
Haplotype Caucasian Rapid disease progression [50]
rs352139G/rs352140G
β-defensin 1 rs11362G/G Caucasian No impact on perinatal HIV infection [52]
Brazilian Low risk of perinatal HIV infection [53]
rs1800972C/C Caucasian High risk of perinatal HIV infection [52]
Caucasian Rapid disease progression [50]
rs1799946A/A Brazilian High risk of perinatal HIV infection [53]
rs1799946G/G Caucasian Low risk of perinatal HIV infection [54]
Haplotype Caucasian Low risk of perinatal HIV infection [54]
rs1800972G/rs352140G
Caucasian Slow disease progression [50]
MBL2 Haplotype XA/XA Argentinian High risk of perinatal HIV infection [58]
Rapid disease progression
TNF-α rs1800629G/G Indian Low risk of perinatal HIV infection [59]
Haplotype 
rs1800629G/rs361525G
IL-1 gene Haplotype Indian High risk of perinatal HIV infection [60]
cluster rs2234650T/rs1800587C/rs16
944C/rs1143634C/rs315952T
HLA B*4901, B*5301 White, African American, Hispanic No impact on perinatal HIV infection [64]
B*18 Kenyan Low risk of perinatal HIV infection [63]
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molecular patterns (PAMPs), shared by large groups of
micro-organisms. Following interactions with their ligands, TLRs
trigger activation of signalling pathways that ultimately induce
cytokine production [43]. TLR7 and TLR8 are expressed on
dendritic cells and monocytes, and recognise the guanosine- and
uridine-rich single-stranded (ss) RNA of HIV-1. After triggering
by viral ssRNA, TLR7 and TLR8 interact with several adaptor
proteins to activate transcription factors, leading to production of
inﬂammatory cytokines and antiviral compounds such as
interferon-α  [44]. TLR9 recognises the cytidine–phosphate–
guanosine (CpG) DNA motifs that are present in many bacteria
and viruses. Activated TLR9 alerts the immune system, triggering
the activation of pro-inﬂammatory reactions and inducing
dendritic cell maturation and production of cytokines [45].
Defensins are small cationic peptides mainly produced by
leukocytes and epithelial cells; according to their size and binding
patterns, they are subgrouped into α, β, and θ [46]. β-defensin 1
is constitutively expressed by epithelial cells, whereas expression
of β-defensins 2 and 3 can be induced by pro-inﬂammatory
cytokines. The antiviral activity of β-defensins involves several
mechanisms, including direct interaction with viral envelopes and
target cells. β-defensins 2 and 3 inhibit HIV spread and replication
through viral inactivation and downregulation of CXCR4, co-
receptor of X4 HIV strains [47].
SNPs in TLR and defensin genes have been associated with
increased susceptibility or protection against several infectious
diseases [47,48]. Genetic polymorphisms and speciﬁc haplotypes
of TLR9 [49–51] and β-defensin 1 [50,52–54] inﬂuence the risk
of perinatal HIV infection and disease outcome in HIV-infected
children (Table 1). An important mechanism by means of which
TLRs and defensins may modulate disease progression is their
role in chronic immune activation. During the course of HIV
infection, the CD4+ cell count (or CD4+ cell percentage in
children under 5 years of age) is the most important indicator of
disease progression. The gut is one of the major sites of CD4 cell
depletion; its damage impairs the mucosal barrier and allows
microbial translocation [55]. Speciﬁc variants of β-defensins may
protect against disease progression by increasing defensin
expression at mucosal level. Microbial translocation allows
bacterial components to enter the bloodstream and trigger TLRs
with consequent production of pro-inﬂammatory cytokines and
induction of a chronic state of immune activation. This immune
activation persists in children who do not respond well to cART,
and is a hallmark of HIV pathogenesis [56] (Figure 2).
Mannose-binding lectin (MBL) is synthesised by the liver and
secreted into the bloodstream, where it plays an important role in
the innate immune defence against invading micro-organisms.
MBL is a plasma pattern-recognition receptor that can mediate
the elimination of pathogens [57]. Speciﬁc genetic variants of
MBL2 have been described to affect the risk of perinatal HIV
infection and progression to AIDS [58].
Genetic variants of cytokines have recently been described to
inﬂuence perinatal HIV infection and disease progression. The
rs1800629GG genotype, responsible for the low expression of
TNF-α, is associated with a lower risk of perinatal transmission
[59]. A speciﬁc haplotype of interleukin (IL)-1 cluster gene has
been found to be associated with increased risk of perinatal
infection [60].
Human leukocyte antigen (HLA) molecules regulate the cellular
immune system by detecting and presenting peptides derived
from infectious agents to T cells. The HLA region includes
128 genes, and a great number of allele variations occur among
individuals. Multiple HLA class 1 alleles have been linked to the
rate of HIV disease progression: HLA alleles B*27, B*58, B2701
are potentially protective [61,62]. HLA B*18 has been associated
with low risk of perinatal infection [63]. HLA B*4901 and B*5301
in mothers have been found to be associated with a lower risk of
MTCT, but in children these alleles are not associated with
infection risk [64]. The HLA-G molecule is of particular interest,
as it is a non-classical MHC class I molecule highly expressed in
the trophoblasts at the maternal–fetal interface. Several SNPs of
HLA-G have been associated with a decreased risk of perinatal
HIV infection [65].
Notably, there are important geographic and ethnic variations in
the frequency of genetic variants, encoding products that may
interfere with HIV infection and the outcome of HIV disease.
Role of early treatments in paediatric HIV/AIDS
HIV preferentially infects activated memory CD4+ cells that
express the chemokine co-receptor CCR5. The majority of
infected cells die quickly, but a small number revert to a resting
state and persist life-long as a latent reservoir [66]. Because cART
blocks nearly all new infection events, the reservoirs that exist at
the time of cART initiation are those which persist throughout
life and impede the eradication of chronic HIV infection.
As recommended by World Health Organization (WHO) [67],
Department of Health and Human Services [68], and Paediatric
European Network for Treatment of AIDS (PENTA) [69] guidelines
for treatment of paediatric HIV infection, cART should be started
as soon as possible in all HIV-infected children, irrespective of
clinical or immunological status. The risks of drug resistance and
early toxicity are markedly outweighed by the reduction of both
short-term mortality and disease progression, especially
prevention of irreversible HIV encephalopathy [70–74] (Table 2).
Evidence from four children, who initiated early cART before the
age of 2.6 months, showed no HIV plasma viraemia for more than
10 years, had no immune response to HIV, and had
replication-competent virus in only one case, all supports the
concept that early cART signiﬁcantly reduces HIV reservoirs [23].
Even cART initiation before 6 months of age seems to reduce viral
reservoirs; in fact, 15 children who initiated cART before the age
HIV
Disease progression
Immune activation
Microbial translocation
Damage to mucosal barrier
cART
Defensins
Specific genetic
variants of TLR
and/or other
innate immune
factors
PAMPs
Activation of TLR pathways
Pro-inflammatory cytokines
Figure 2. Model of host factors and early treatments to prevent early disease
progression. Defensins may counteract damage to mucosal barriers due to
HIV. Microbial translocation generated by damage of mucosal barriers, and
HIV itself, activate Toll-like receptors (TLRs) that recognise and bind
pathogen-associated molecular patterns (PAMPs), shared by large groups
of micro-organisms. Following interactions with their ligands, TLRs trigger
activation of signalling pathways that promote pro-inﬂammatory cytokines
and thus immune activation, a hallmark of disease progression. Speciﬁc
genetic variants of TLRs that modify their activity and other components of
innate immunity may restrict immune activation and disease progression
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Table 2. Viro-immunology parameters in early-treated infants
Study population Viro-immunological parameters Main findings Refs
CMIR: cell-mediated immune response
Multicentre nationwide case–control
study
30 infants with early cART
(<6 months) vs 103 infants with
deferred cART (>6 months)
HIV plasma viraemia
CD4 cells
CD8 cells
• 73% early cART vs 30% deferred cART reached undetectable viral load
• Higher % CD4 cells in early cART than in deferred cART
• Lower % CD8 cells in early cART than in deferred cART
• No disease progression in early cART vs 43% disease progression in
deferred cART (median follow-up 4.1 years)
[70]
European Collaborative Study
124 infants with early cART
(<3 months) vs 86 infants with
deferred cART (>3 months)
96 infants with early cART
(<3 months) vs infants with deferred
cART (22: 3–6 months and
21: 6—12 months)
HIV plasma viraemia
CD4 cells
• Lower risk of AIDS/death in early ART than in deferred ART (1.6% vs
11.6% at 1 year follow-up)
• Lower decline of % CD4 cells over ﬁrst year of life in early cART than in
deferred cART groups
• Time from cART initiation to ﬁrst virological suppression shorter in early
cART than in deferred cART groups
• Trend to lower HIV plasma viraemia between 12 and 48 months in early
cART than in deferred cART groups
[71
[72]
4 infants with early cART
(<2.6 months) vs 4 children with
late cART
HIV plasma viraemia
HIV DNA 
HIV serology
Virus culture
CMIR to HIV
CD4, CD8 cell subsets
• Plasma viraemia undetectable in all early-treated
• HIV DNA in peripheral blood cells lower in early-treated than in
late-treated
HIV seropositivity in 1/4 early-treated vs 4/4 late-treated
CMIR to HIV epitopes in 0/4 early-treated vs 4/4 late-treated
• Normal level of CD8 activated cells in early-treated 
[23]
15 infants with early cART
(<6 months)
HIV plasma viraemia
HIV DNA
2-LTR
HIV serology
CMIR to HIV
• Median time of suppression plasma viraemia: 6 years
• 60% with undetectable HIV DNA in CD4+ cells
• No detectable 2-LTR circles
• 47% HIV-seronegative,
• Only 1 with detectable CMIR to HIV epitopes
[75]
6 infants with early cART
(<3 months) discontinuation of cART
in 2 children at 3–4 years of age
HIV plasma viraemia
Cell-associated HIV RNA
HIV DNA
Virus culture
HIV-serology
CMIR to HIV
CD4, CD8 cell subsets
• Decline of HIV plasma viraemia to undetectable levels in all cases
• Persistence of HIV DNA in 4, and cell-associated HIV RNA in 2 
• Lack of HIV autochthonous antibodies in 4 children
• Lack of CMIR to HIV
• All viro-immunological parameters persistently negative in 2 children for
up to 4 years follow-up
• cART interruption in 2 children, 1 positive and 1 negative for all viro-
immunological parameters: rebound of HIV plasma viraemia in both
[22]
CHER Trial
252 infants with early cART
(<3 months: 126 cART for 40 weeks;
126 cART for 96 weeks) vs
125 infants with deferred ART
4.8 years follow-up
Substudy
12 infants with cART initiation
<2 months vs 8 with cART initiation
>2 months
HIV plasma viraemia
HIV DNA
Cell-associated HIV RNA
• Lower risk of death (4% vs 16%) and disease progression (6% vs 26%) in
early cART than in deferred cART group at median 40-week follow-up
• 25% early ART-40W, 21% early ART-96 W and 38% deferred ART
reached the primary endpoint (failure of ﬁrst-line cART) or death
• After 7–8 years of continuous cART, children starting cART <2 months of
age had lower HIV DNA and cell-associated HIV RNA than children who
started cART >2 months of age
[73]
[74]
[77]
[78]4 infants with early cART
(within 72 hours of life)
HIV plasma viraemia
Cell-associated HIV RNA
HIV DNA, CD4 cells
Virus culture
HIV serology
CMIR to HIV
HLA genotype
• At 2.5–7.5 years of follow-up: negative for all parameters (HIV serology,
CMIR to HIV, ultrasensitive HIV plasma viraemia, HIV DNA in CD4 cells)
• Low level of cell-associated HIV RNA 
• Normal CD4 cell count
• Viral rebound in 2, due to poor adherence to cART
[79]
[80]
1 infant with early cART
(initiated by 30 hours of life and
discontinued at 18 months)
HIV plasma viraemia 
HIV DNA
Virus culture
HIV serology
CMIR to HIV
HLA genotype
CD4 cells, CD8 cells
• HIV seronegative at 24, 26 and 28 months of age
• No HIV-speciﬁc cellular immune response
• No rebound of HIV plasma viraemia & HIV DNA after therapy interruption
• Normal CD4 and CD8 cell count after therapy interruption
• After 46 months’ follow-up (27 months after cART discontinuation)
rebound of HIV plasma viraemia and onset of autochthonous
HIV-speciﬁc antibodies
[81]1 infant with early cART
(initiated at 12 hours and
discontinued at 3 years)
HIV plasma viraemia
HIV DNA
Virus culture
HIV serology, CD4,
CD8 cell subsets
• Persistently undetectable plasma viraemia after the initial decline 
• Negative for HIV DNA, virus culture and HIV-serology at 3 years
• Increased number of  activated CD4 and CD8 cells at 3 years
• Rebound of HIV plasma viraemia within 2 weeks after cART interruption
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of 6 months showed a median duration of 6 years of undetectable
plasma viraemia; 60% of them had undetectable integrated HIV
DNA, and none had detectable 2-LTR circles, a marker of residual
viral replication during cART. Of these children, 47% were
seronegative and all except one had undetectable cell-mediated
immune response against HIV epitopes [75]. While early cART is
efﬁcient in reducing mortality and disease progression, the need
for life-long therapy due to the early establishment of latent HIV
reservoirs is a problem.
Studies on the natural history of paediatric HIV infection
suggested that cART in neonates may prevent the establishment
of HIV reservoirs and systemic chronic HIV infection. The ﬁrst
study that speciﬁcally addressed this aspect involved six infants
who started cART within 3 months of life [22]. All of them
showed a decline in plasma viraemia to undetectable levels. HIV
DNA persisted in the peripheral blood cells in four of these
children, but only two had detectable intracellular HIV mRNA. All
viral parameters remained persistently negative in two children.
Only two children produced HIV antibodies; the others, after
having lost maternal antibodies, remained seronegative. Therapy
was interrupted in two children: one a 3-year-old, positive for all
viro-immunological parameters, and one a 4-year-old, negative
for all viro-immunological parameters. In particular, the
seronegative child had received zidovudine at birth and started
cART at 11 weeks of age. At 13 months, the child lost maternal
antibodies and remained seronegative. Persistent undetectable
HIV plasma viraemia, proviral HIV DNA and intracellular HIV
mRNA, plus no autochthonous HIV antibody production by IVAP
assay (at 18 months) and no HIV-speciﬁc immune response by
EliSpot assay (at 38 months) all strongly suggested viral clearance
[22]. Further analyses with CD25 and CD38 markers on CD4+ and
CD8+ lymphocytes (at 38 and 46 months) disclosed no signs of
immune activation [76]. Rebound of HIV plasma viraemia
occurred within 2 weeks after ART interruption, was more rapid
than that observed in the seropositive child, and preceded
detection of HIV DNA and HIV mRNA in peripheral blood cells,
thus indicating that the HIV reservoir was outside the peripheral
blood compartment [22].
Of particular interest is the Children with HIV Early Antiretroviral
Therapy (CHER) trial [73,74]. In this trial, 377 HIV-infected
infants with a median age of 7.4 weeks were randomly allocated
to one of three groups: deferred cART (ART-Def), immediate ART
for 40 weeks (ART-40W) or immediate ART for 96 weeks (ART-
96W) with subsequent interruption of treatment. Criteria for ART
initiation in the ART-Def group and re-initiation after interruption
were CD4% less than 25% in the ﬁrst year; otherwise the criteria
were CD4% less than 20% or stage B or stage C. Median time to
cART initiation in the ART-Def group was 20 weeks; the time to
restarting cART after interruption was 33 weeks in ART-40W and
70 weeks in ART-96W group. At the median follow-up of 40
weeks, the early-treated children had lower risk of death and
disease progression than infants in the ART-Def group [73]. At
the median follow-up of 4.8 years, 38% in ART-Def, 25% in ART-
40W and 21% in the ART-96W group reached the primary end-
point (immunological, clinical or virological failure of ﬁrst-line
cART) or death. Thus, early cART had better clinical and
immunological outcomes than deferred ART. Additionally, children
randomised to 96W of ART had a longer period off therapy
compared with those allocated to 40W [74]. Some of the children
initially randomly allocated to early-limited ART in the CHER trial
did not interrupt cART; a substudy conducted in 20 of these
infants who initiated cART <8 weeks of age (n=12) or >8 weeks
of age (n=8) and remained for 7–8 years with undetectable HIV
plasma viraemia (below 400 HIV RNA copies/mL) showed that
the children who initiated cART earlier had lower levels of HIV
DNA and intracellular HIV RNA than children who started later
[77]. This ﬁnding may indicate that starting cART a few
days/weeks after birth may change the size of the HIV reservoir.
Studies on HIV serology and kinetics of HIV rebound after
therapy interruption in the CHER trial will be very important to
understand this mechanism.
In another study, initiation of cART within 72 hours after birth was
carried out as perinatal exposure prophylaxis in high-risk situations
(i.e. mothers with detectable viral load and/or poor adherence to
therapy) [78]. In this study, four of 12 infants recognised to be
HIV-infected achieved sustained virological suppression. These
children, after having lost maternal antibodies, remained HIV-
seronegative and the EliSpot assay revealed no detectable
cell-mediated immune response against several HIV epitopes. At
2.5–7.5 years, all four children were negative for HIV DNA and had
a low level of cell-associated HIV mRNA in their peripheral blood
CD4+ cells. Three of these children had the B*58 allele and
HLA-B sequence variations associated with better HIV control.
Two of them underwent viral rebound, due to poor adherence
after several years of effective therapy [78].
An interesting case was the infant termed the ‘Mississippi Baby’
in whom cART had been started at 30 hours of life. After cART
discontinuation at 18 months, the infant remained negative for
HIV plasma viraemia, HIV DNA in peripheral blood cells, HIV
antibodies and cell-mediated immune responses against HIV gag
and nef epitopes [79]. However, after 27 months of cART
discontinuation, the child had a rebound of HIV plasma viraemia
together with the onset of HIV-speciﬁc antibodies [80]. This case
suggested that very early cART may alter the establishment of
long-term persistence of HIV infection; the rebound of plasma
viraemia after a substantial period of viral remission may be
consistent with the model of HIV latency in long-lived resting
memory CD4+ cells. This case indicates that early cART restricts,
but does not eradicate HIV reservoirs, once they have been
established.
A case has recently been reported in which zidovudine and
nevirapine prophylaxis initiated within 12 hours of birth was
followed by cART a few days later, when the infant was
recognised to be HIV-infected [81]. At 3 years of age, the child
was seronegative, had undetectable HIV plasma viraemia,
undetectable HIV DNA in peripheral blood cells, but had an
increased number of activated cells together with HIV-speciﬁc
cytotoxic T lymphocytes. When cART was discontinued, HIV
plasma viraemia rebounded in 2 weeks [81]. The authors
suggested that presence of immune activation, impairment of
naïve/memory cells and cytotoxic T lymphocytes may predict
rebound rather than remission of HIV after cART discontinuation.
The solution is not so simple. Indeed, as observed previously,
rebound of plasma viraemia after cART discontinuation also
occurred in an early-treated child without any virological and
immunological signs of HIV infection [22]. Thus, the absence of
virological and immunological signs of HIV infection in
early-treated infants is important, but not sufﬁcient to exclude
viral rebound after therapy interruption.
Conclusions
A few cases have suggested that, although MTCT does occur,
the virus cannot establish persistent infection in the infant, thus
raising the possibility of transient infection followed by natural
clearance of HIV [12–16]. Virus–host interactions contribute
towards deﬁning the threshold level required for the
establishment of life-long persistence of HIV infection. HIV is
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characterised by a high degree of genotypic and phenotypic
variability, which involves a multitude of interactions with the
host. In neonates who acquire infection when their immune
system is still developing, innate resistance and/or immunity may
be the principal drivers in restricting perinatal infection and early
disease progression.
Several genetic variants of viral co-receptors and their ligands
inﬂuence perinatal HIV infection and the onset of early AIDS,
according to the co-receptor usage of transmitted/infecting viral
strains. Regardless of the biological and genetic variability of HIV,
data indicate that the genetic variants of TLRs and defensins,
key elements of innate immunity, inﬂuence the risk of MTCT, the
establishment of perinatal infection, and the outcome of
paediatric HIV disease. Although the mechanism by means of
which these variants inﬂuence HIV interaction with the host are
still largely unknown, TLR and defensins may play a critical role
in the onset and persistence of immune activation, a hallmark of
HIV disease.
The main effect of early cART is to decrease the HIV load to below
the level required for the onset of the immune response to HIV.
The majority of children who initiated cART within 3 months of
age, after having lost passively transferred maternal antibodies, did
remain seronegative and did not develop immune responses
against HIV epitopes [22,23,75,78]. Early cART also signiﬁcantly
reduced HIV reservoirs [23,75,77]. During continuous cART, early-
treated children remained persistently HIV seronegative, with
undetectable HIV plasma viraemia and undetectable or very low
levels of cell-associated HIV DNA and HIV RNA. Despite long
periods with no signs or symptoms of HIV infection, all early cART-
treated children who underwent cART discontinuation had
rebound of HIV in within 2–3 weeks [22,81], except for one child
who had a 27-month period of viral remission [80]. In addition,
early cART may restrict but not eliminate HIV reservoirs. Thus,
early cART is quite efﬁcient in decreasing mortality and disease
progression, but is unable to eradicate infection. Could cART
prevent the establishment of HIV reservoirs and life-long
establishment of HIV infection? cART interruption with a long
follow-up may be the only practical way of determining the effect
of early treatment, but which parameters should be analysed in
children with no signs of HIV infection before stopping cART?
Answers to these questions are also important in order to optimise
the use of early cART in infants at high risk of HIV infection.
Acknowledgments
Raffaella Petrara is a fellow recipient of AIRC Grant no. IG-13233,
Principal Investigator D.Serraino, CRO Aviano. Riccardo Freguja is
a fellow recipient of PENTA Foundation
References
1. UNAIDS. Report on the Global AIDS Epidemic 2013. Available at:
www.unaids.org/en/media/unaids/contentassets/documents/epidemiology/2013
/gr2013/UNAIDS_Global_Report_2013_en.pdf (accessed May 2015).
2. Working Group on Mother-To-Child Transmission of HIV. Rates of mother-to-child
transmission of HIV-1 in Africa, America, and Europe: results from 13 perinatal
studies. J Acquir Immune Defic Syndr Hum Retrovirol 1995; 8:506–510.
3. Dunn D; HIV Paediatric Prognostic Markers Collaborative Study Group. Short-term
risk of disease progression in HIV-1-infected children receiving no antiretroviral
therapy or zidovudine monotherapy: a meta-analysis. Lancet 2003; 362:
1605—1611.
4. Little K, Thorne C, Luo C et al. Disease progression in children with vertically
acquired HIV infection in sub-Saharan Africa: reviewing the need for HIV treatment.
Curr HIV Res 2007; 5: 139–153.
5. European Collaborative Study. Mother-to-child transmission of HIV infection in the
era of highly active antiretroviral therapy. Clin Infect Dis 2005; 40: 458–465.
6. European Collaborative Study. Maternal viral load and vertical transmission of
HIV-1: an important factor but not the only one. AIDS 1999; 13: 1377–1385.
7. De Rossi A. Virus–host interactions in paediatric HIV-1 infection. Curr Opin HIV
AIDS 2007; 2: 399–404.
8. Mofenson LM. Prevention in neglected subpopulations: prevention of mother-to-
child transmission of HIV infection. Clin Infect Dis 2010; 50 Suppl 3: S130–148.
9. Sketty AK. Epidemiology of HIV infection in women and children: a global
perspective. Curr HIV Res 2013; 11: 81–92.
10. Drake AL, Wagner A, Richardson B, John-Stewart G. Incident HIV during pregnancy
and postpartum and risk of mother-to-child HIV transmission: a systematic review
and meta-analysis. PLoS Med 2014; 11: e1001608.
11. King CC, Ellington SR, Kourtis AP. The role of co-infections in mother-to-child
transmission of HIV. Curr HIV Res 2013; 11: 10–23.
12. Bryson YJ, Pang S, Wei LS et al. Clearance of HIV infection in a perinatally infected
infant. N Engl J Med 1995; 332: 833–838.
13. Roques PA, Gras G, Parnet-Mathieu F et al. Clearance of HIV infection in 12
perinatally infected children: clinical, virological and immunological data. AIDS
1995; 9: F19–26.
14. Newell ML, Dunn D, De Maria A et al. Detection of virus in vertically exposed HIV-
antibody negative children. Lancet 1996; 347: 213–215.
15. Frenkel LM, Mullins JI, Leran GH et al. Genetic evaluation of suspected cases of
transient HIV-1 infection of infants. Science 1998; 280: 1073–1077.
16. Vazquez Perez JA, Basulado Sigales MC, Reyes-Teran G et al. Human
immunodeﬁciency virus type 1 in seronegative infants born to HIV-1-infected
mothers. Virol J 2006; 3: 52–57.
17. Giaquinto C, De Rossi A. 9-year-old child with falling CD4 count after neonatal HIV.
Lancet 1995; 346: 963.
18. Wade NA, Birkhead GS, Warren BL et al. Abbreviated regimens of zidovudine
prophylaxis and perinatal transmission of the human immunodeﬁciency virus.
N Engl J Med 1998; 339: 1409–1414.
19. Gray GE, Urban M, Chersich MF et al.; PEP Study Group. A randomized trial of two
postexposure prophylaxis regimens to reduce mother-to-child HIV-1 transmission
in infants of untreated mothers. AIDS 2005; 19: 1289–1297.
20. De Rossi A, Masiero S, Giaquinto C et al. Dynamics of viral replication in infants
with vertically acquired human immunodeﬁciency virus type 1 infection. J Clin Invest
1996; 97: 323–330.
21. Lohman BL, Slyker JA, Richardson BA et al. Longitudinal assessment of human
immunodeﬁciency virus type 1 (HIV-1)-speciﬁc gamma interferon responses during
the ﬁrst year of life in HIV-1-infected infants. J Virol 2005; 79: 8121–8130.
22. Zanchetta M, Anselmi A, Vendrame D et al. Early therapy in HIV-1-infected children:
effect on HIV-1 dynamics and HIV-1-speciﬁc immune response. Antivir Ther 2008;
13: 47–55.
23. Luzuriaga K, Tabak B, Garber M et al. HIV type 1 (HIV-1) proviral reservoirs decay
continuously under sustained virologic control in HIV-1-infected children who
received early treatment. J Infect Dis 2014; 210: 1529–1538.
24. Klatt NR, Bosinger SE, Peck M et al. Limited HIV infection of central memory and
stem cell memory CD4+ T cells is associated with lack of progression in viremic
individuals. Plos Pathog 2014, 10: e1004345. 
25. Salvatori F, Masiero S, Giaquinto C et al. Evolution of human immunodeﬁciency
virus type 1 in perinatally infected infants with rapid and slow progression to
disease. J Virol 1997; 71: 4694–4706.
26. Ometto L, Bertorelle R, Mainardi M et al. Polymorphisms in the CCR5 promoter
region inﬂuence disease progression in perinatally human immunodeﬁciency virus
type 1-infected children. J Infect Dis 2001; 183: 814–818.
27. Cavarelli M, Karlsson I, Zanchetta M et al. HIV-1 with multiple CCR5/CXCR4
chimeric receptor use is predictive of immunological failure in infected children.
PLoS One 2008; 3: e3292.
28. Gianesin K, Freguja R, Carmona F et al. The role of genetic variants of stromal
cell-derived factor 1 in pediatric HIV-1 infection and disease progression. PLoS One
2012; 7: e44460.
29. Liu R, Paxton WA, Choe S et al. Homozygous defect in HIV-1 coreceptor accounts
for resistance of some multiply exposed individuals to HIV-1 infection. Cell 1996;
86: 367–377.
30. Singh KK, Barroga CF, Hughes MD et al. Genetic inﬂuence of CCR5, CCR2, and
SDF1 variants on human immunodeﬁciency virus 1 (HIV-1)-related disease
progression and neurological impairment, in children with symptomatic HIV-1
infection. J Infect Dis 2003; 188: 1461–1472.
31. Singh KK, Hughes MD, Chen J et al. Associations of chemokine receptor
polymorphisms with HIV-1 mother-to-child transmission in sub-Saharan Africa:
possible modulation of genetic effects by antiretrovirals. J Acquir Immune Defic
Syndr 2008; 49: 259–265.
32. Ioannidis JP, Contopoulos-Ioannidis DG, Rosenberg PS et al.; HIV Host Genetics
International Meta-Analysis Group. Effects of CCR5-delta32 and CCR2-64I alleles
on disease progression of perinatally HIV-1-infected children: an international meta-
analysis. AIDS 2003; 17: 1631–1638.
33. de Souza PR, Arraes LC, de Lima Filho JL et al. CCR5 promoter polymorphisms and
HIV-1 perinatal transmission in Brazilian children. J Reprod Immunol 2006; 69:
77—84.
34. Lusso P. HIV and the chemokine system: 10 years later. EMBO J 2006; 25: 447—456.
35. Lehner T. The role of CCR5 chemokine ligands and antibodies to CCR5 coreceptors
in preventing HIV infection. Trends Immunol 2002; 23: 347–351.
36. Shao W, Tang J, Song W et al. CCL3L1 and CCL4L1: variable gene copy number in
adolescents with and without human immunodeﬁciency virus type 1 (HIV-1)
infection. Genes Immun 2007; 8: 224–231.
37. Meddows-Taylor S, Donninger SL, Paximadis M et al. Reduced ability of newborns
to produce CCL3 is associated with increased susceptibility to perinatal human
immunodeﬁciency virus 1 transmission. J Gen Virol 2006; 87: 2055–2065.
38. Kuhn L, Schramm DB, Donninger S et al. African infants’ CCL3 gene copies
inﬂuence perinatal HIV transmission in the absence of maternal nevirapine. AIDS
2007; 21: 1753–1761.
39. Tresoldi E, Romiti ML, Boniotto M et al.; European Shared Cost Project Group;
Italian Register for HIV Infection in Children. Prognostic value of the stromal
Host factors and early treatments  147
Journal of Virus Eradication 2015; 1: 140—147 PENTA-ID ·  REVIEW
cell-derived factor 1 3'A mutation in pediatric human immunodeﬁciency virus type
1 infection. J Infect Dis 2002; 185: 696–700.
40. Boily-Larouche G, Iscache AL, Zijenah LS et al. Functional genetic variants in
DC-SIGNR are associated with mother-to-child transmission of HIV-1. PLoS One
2009; 4: e7211.
41. Boily-Larouche G, Milev MP, Zijenah LS et al. Naturally-occurring genetic variants
in human DC-SIGN increase HIV-1 capture, cell-transfer and risk of mother-to-child
transmission. PLoS One 2012; 7: e40706.
42. Bellusci CP, Rocco CA, Aulicino PC et al. MDR1 3435T and 1236T alleles delay
disease progression to pediatric AIDS but have no effect on HIV-1 vertical
transmission. AIDS 2010; 24: 833–840.
43. Akira S. TLR signaling. Curr Top Microbiol Immunol 2006; 311: 1–16.
44. Heil F, Hemmi H, Hochrein H et al. Species-speciﬁc recognition of single-stranded
RNA via toll-like receptor 7 and 8. Science 2004; 303: 1526–1529.
45. Barton GM, Kagan JC. A cell biological view of Toll-like receptor function: regulation
through compartmentalization. Nat Rev Immunol 2009; 9: 535–542.
46. Klotman ME, Chang TL. Defensins in innate antiviral immunity. Nat Rev Immunol
2006; 6: 447–456.
47. Seidel A, Ye Y, de Armas LR et al. Cyclic and acyclic defensins inhibit human
immunodeﬁciency virus type-1 replication by different mechanisms. PLoS One
2010; 5: e9737.
48. Freguja R, Gianesin K, Zanchetta M, De Rossi A. Cross-talk between virus and host
innate immunity in pediatric HIV-1 infection and disease progression. New Microbiol
2012; 35: 249–257.
49. Ricci E, Malacrida S, Zanchetta M et al. Toll-like receptor 9 polymorphisms inﬂuence
mother-to-child transmission of human immunodeﬁciency virus type 1. J Transl Med
2010; 8: 49.
50. Freguja R, Gianesin K, Del Bianco P et al. Polymorphisms of innate immunity genes
inﬂuence disease progression in HIV-1-infected children. AIDS 2012; 26: 765–768.
51. Beima-Soﬁe KM, Bigham AW, Lingappa JR et al. Toll-like receptor variants are
associated with infant HIV-1 acquisition and peak plasma HIV-1 RNA level. AIDS
2013; 27: 2431–2439.
52. Braida L, Boniotto M, Pontillo A et al. A single-nucleotide polymorphism in the
human beta-defensin 1 gene is associated with HIV-1 infection in Italian children.
AIDS 2004; 18: 1598–1600.
53. Milanese M, Segat L, Pontillo A et al. DEFB1 gene polymorphisms and increased risk
of HIV-1 infection in Brazilian children. AIDS 2006; 20: 1673–1675.
54. Ricci E, Malacrida S, Zanchetta M et al. Role of beta-defensin-1 polymorphisms in
mother-to-child transmission of HIV-1. J Acquir Immune Defic Syndr 2009; 51: 13–
19.
55. Brenchley JM, Price DA, Schacker TW et al. Microbial translocation is a cause of
systemic immune activation in chronic HIV infection. Nat Med 2006; 12:
1365—1371.
56. Anselmi A, Vendrame D, Rampon O et al. Immune reconstitution in human
immunodeﬁciency virus type 1-infected children with different virological responses
to anti-retroviral therapy. Clin Exp Immunol 2007; 150: 442–450.
57. Petersen SV, Thiel S, Jensenius JC. The mannan-binding lectin pathway of
complement activation: biology and disease association. Mol Immunol 2001; 38:
133–149.
58. Mangano A, Rocco C, Marino SM et al. Detrimental effects of mannose-binding
lectin (MBL2) promoter genotype XA/XA on HIV-1 vertical transmission and AIDS
progression. J Infect Dis 2008; 198: 694–700.
59. Ahir S, Mania-Pramanik J, Chavan V et al. Genetic variation in the promoter region
of pro-inﬂammatory cytokine TNF-  in perinatal HIV transmission from Mumbai,
India. Cytokine 2015; 72: 25–30.
60. Ahir S, Chaudhari D, Chavan V et al. Polymorphisms in IL-1 gene cluster and its
association with the risk of perinatal HIV transmission, in an Indian cohort.
Immunol Lett 2013; 153: 1–8.
61. Pereyra F, Jia X, McLaren PJ et al.; International HIV Controllers Study. The major
genetic determinants of HIV-1 control affect HLA class I peptide presentation.
Science 2010; 330: 1551–1557.
62. Goulder PJ, Walker BD. HIV and HLA class I: an evolving relationship. Immunity
2012; 37: 426–440.
63. Farquhar C, Rowland-Jones S, Mbori-Ngacha D et al. Human leukocyte antigen
(HLA) B*18 and protection against mother-to-child HIV type 1 transmission.
AIDS Res Hum Retroviruses 2004; 20: 692–697.
64. Winchester R, Pitt J, Charurat M et al. Mother-to-child transmission of HIV-1:
strong association with certain maternal HLA-B alleles independent of viral load
implicates innate immune mechanisms. J Acquir Immune Defic Syndr 2004; 36: 659–
670.
65. Aikhionbare FO, Kumaresan K, Shamsa F, Bond VC. HLA-G DNA sequence variants
and risk of perinatal HIV-1 transmission. AIDS Res Ther 2006; 3: 28.
66. Chomont N, El-Far M, Ancuta P et al. HIV reservoir size and persistence are driven
by T cell survival and homeostatic proliferation. Nat Med 2009; 15: 893–900.
67. WHO. Consolidated guidelines on the use of antiretroviral drugs for treating and
preventing HIV infection: recommendations for a public health approach. 2013
Available at http://apps.who.int/iris/bitstream/10665/85321/1/
9789241505727_eng.pdf?ua=1 (accessed May 2015).
68. Department of Health and Human Services. Panel on antiretroviral therapy and
medical management of HIV-infected children. Guidelines for the use of
antiretroviral agents in pediatric HIV infection. 2015. Available at
http://aidsinfo.nih.gov/guidelines/html/2/pediatric-treatment-guidelines/0
(accessed May 2015)
69. Bamford A, Turkova A, Lyall H et al.; PENTA Steering Committee. Paediatric
European Network for Treatment of AIDS (PENTA) guidelines for treatment of
paediatric HIV-1 infection 2015: optimizing health in preparation for adult life.
HIV Med 2015 [Epub ahead of print].
70. Chiappini E, Galli L, Tovo PA et al.; Italian Register for HIV Infection in Children.
Virologic, immunologic, and clinical beneﬁts from early combined antiretroviral
therapy in infants with perinatal HIV-1 infection. AIDS 2006; 20: 207–215.
71. Goetghebuer T, Haelterman E, Le Chenadec J et al.; European Infant Collaboration
group. Effect of early antiretroviral therapy on the risk of AIDS/death in
HIV-infected infants. AIDS 2009; 23: 597–604.
72. Goetghebuer T, Le Chenadec J, Haelterman E et al. Short- and long-term
immunological and virological outcome in HIV-infected infants according to the
age at antiretroviral treatment initiation. Clin Infect Dis 2012; 54: 878–881.
73. Violari A, Cotton MF, Gibb DM et al.; CHER Study Team. Early antiretroviral therapy
and mortality among HIV-infected infants. N Engl J Med 2008; 359: 2233–2244.
74. Cotton MF, Violari A, Otwombe K et al.; CHER Study Team. Early time-limited
antiretroviral therapy versus deferred therapy in South African infants infected with
HIV: results from the children with HIV early antiretroviral (CHER) randomised trial.
Lancet 2013; 382: 1555–1563.
75. Ananworanich J, Puthanakit T, Suntarattiwong P et al.; HIV-NAT 194 Study Group.
Reduced markers of HIV persistence and restricted HIV-speciﬁc immune responses
after early antiretroviral therapy in children. AIDS 2014; 28: 1015–1020.
76. Freguja R, Gianesin K, Mosconi I et al. Regulatory T cells and chronic immune
activation in human immunodeﬁciency virus 1 (HIV-1)-infected children.
Clin Exp Immunol 2011; 164: 373–380.
77. van Zyl GU, Bedison MA, van Rensburg AJ, Laughton B, Cotton MF, Mellors JW.
Early antiretroviral therapy in South African children reduces HIV-1-infected cells
and cell-associated HIV-1 RNA in blood mononuclear cells. J Infect Dis 2014
[Epub ahead of print].
78. Bitnun A, Samson L, Chun TW et al. Early initiation of combination antiretroviral
therapy in HIV-1-infected newborns can achieve sustained virologic suppression
with low frequency of CD4+ T cells carrying HIV in peripheral blood. Clin Infect Dis
2014; 59: 1012–1019.
79. Persaud D, Gay H, Ziemniak C et al. Absence of detectable HIV-1 viremia after
treatment cessation in an infant. N Engl J Med 2013; 369: 1828–1835.
80. Luzuriaga K, Gay H, Ziemniak C et al. Viremic relapse after HIV-1 remission in a
perinatally infected child. N Engl J Med 2015; 372: 786–788.
81. Giacomet V, Trabattoni D, Zanchetta N et al. No cure of HIV infection in a child
despite early treatment and apparent viral clearance. Lancet 2014; 384: 1320.
